Form 4: Rowland Thomas Andrew reports disposition transactions in ANIP

Rhea-AI Filing Summary

Rowland Thomas Andrew reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 1,762 shares at a weighted average price of $76.25 per share. Following the reported transactions, holdings were 39,160 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rowland Thomas Andrew

Role SVP, HEAD - ESTABLISHED BRANDS

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,762	$76.25	$134K

Holdings After Transaction: Common Stock — 39,160 shares (Direct)

Footnotes (1)

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,788 performance stock units, the grant of which was previously reported. Includes 128 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c).

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rowland Thomas Andrew

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, HEAD - ESTABLISHED BRANDS

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		F(1)		1,762	D	$76.25	39,160(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,788 performance stock units, the grant of which was previously reported.

2. Includes 128 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	/s/ Thomas Rowland, by attorney-in-fact Meredith W. Cook	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Thomas Andrew Rowland?

ANI Pharmaceuticals reported a tax-withholding disposition by executive Thomas Andrew Rowland. On February 11, 2026, 1,762 common shares were withheld at $76.25 per share to satisfy tax obligations arising from the vesting of 5,788 performance stock units previously granted to him.

Was the ANI Pharmaceuticals (ANIP) Form 4 transaction an open-market sale?

The Form 4 does not show an open-market sale. It reports a transaction coded “F,” meaning 1,762 shares of common stock were withheld to pay tax liabilities related to vesting performance stock units, rather than shares being sold in the open market.

How many ANI Pharmaceuticals (ANIP) shares does Thomas Andrew Rowland own after the reported transaction?

Following the February 11, 2026 transaction, Thomas Andrew Rowland beneficially owned 39,160 ANI Pharmaceuticals common shares directly. This total includes 128 shares acquired through the ANI Pharmaceuticals Employee Stock Purchase Plan in transactions that were exempt under specified Rule 16b-3 provisions.

What triggered the tax-withholding disposition reported by ANI Pharmaceuticals (ANIP)?

The tax-withholding disposition was triggered by the vesting of 5,788 performance stock units previously granted to Thomas Andrew Rowland. Shares were withheld to cover tax obligations, and this event is described as exempt under Rule 16(b)-3 in the accompanying Form 4 footnote.

What does transaction code "F" mean in the ANI Pharmaceuticals (ANIP) Form 4 filing?

Transaction code “F” indicates payment of an exercise price or tax liability by delivering securities. In this Form 4, 1,762 shares of ANI Pharmaceuticals common stock were withheld to satisfy Rowland’s tax obligations tied to vesting performance stock units, rather than representing a discretionary sale.

How were Employee Stock Purchase Plan shares reported for ANI Pharmaceuticals (ANIP) executive Thomas Rowland?

The Form 4 notes that Rowland’s holdings include 128 ANI Pharmaceuticals common shares acquired under the company’s Employee Stock Purchase Plan. These purchases occurred in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c), and are counted in his 39,160 directly owned shares.